Copy Link Print Information

Aurora B Antibody (YA6131)

(Synonyms: AURKB; AIK2; AIM1; AIRK2; ARK2; STK1; STK12; STK5; Aurora kinase B; Aurora 1; Aurora- and IPL1-like midbody-associated protein 1; AIM-1; Aurora/IPL1-related kinase 2; ARK-2; Aurora-related kinase 2; STK-1; Serine/threonine-protein kinase 12)
Customer Review

Based on 1 Customer Validation

Aurora B Antibody (YA6131) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Aurora B.

For research use only. We do not sell to patients.
  • Host:

    Rabbit

  • Isotype:

    IgG

  • Application:

    WB, IHC-P, ICC/IF, IP, ELISA

  • Reactivity :

    Human

  • Formulation:

    Supplied in PBS, 50% glycerol, 0.05% Proclin 300, 0.05%BSA

  • Conjugation:
    Non-conjugated
  • Experimental Validation Results for Aurora B Antibody (YA6131)
  • Experimental Validation Results for Aurora B Antibody (YA6131)
  • Aurora B Antibody (YA6131) Product Image
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Service
Data Download
Related Products:
Top Publications Citing

Use of MCE Products

Applications

Application
IHC-P Info
IHC-P: Immunohistochemistry-Paraffin
WB Info
WB: Western Blot
ICC/IF Info
ICC/IF: Immunocytochemistry/
Immunofluorescence
ELISA Info
ELISA: Enzyme Linked Immunosorbent Assay
IP Info
IP: Immunoprecipitation
Dilution Ratio 1:500-1:1000 1:1000-1:5000 1:200-1:1000 1:5000-1:20000 1:50-1:200

Product Details

Description

Aurora B Antibody (YA6131) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Aurora B.

  • Host Rabbit
  • Clonality Monoclonal
  • Species Reactivity
    Human
  • Observed Molecular Weight
    Observed band size: 39 kDa Info
    Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
  • Calculated Molecular Weight Predicted band size: 39 kDa
Purification

Protein A

Conjugation

Non-conjugated

Modification

Unmodified

Isotype

IgG

Product Properties

  • Appearance

    Solution

  • Formulation

    Supplied in PBS, 50% glycerol, 0.05% Proclin 300, 0.05%BSA

  • Concentration

    Batch-dependent, Please check the COA for the concentration of each lot. Check Lot Concentration

  • Storage & Stability

    Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

  • Shipping

    Shipping with blue ice.

Verification Images

  • Experimental Validation Results for Aurora B Antibody (YA6131)
    Western blot analysis was performed on protein extracts (25 μg) from HepG2 (lane 2), A549 (lane 3), Caco-2 (lane 4), MCF-7 (lane 5), HeLa (lane 6), and HT-1080 (lane 7) using Aurora B antibody. Proteins were transferred onto a 0.45 μm PVDF membrane using the Trans-Blot® Turbo™ system for 13 min. The membrane was then blocked with 5% nonfat milk in TBST (HY-K1025) for 1 h at room temperature. Thhe primary antibody (1:1000) and loading control antibody GAPDH Antibody (HRP) (HY-P80954A) (1:2500) were diluted in 5% nonfat milk in TBST and incubated with the membrane overnight at 4°C. After washing, the membrane of primary antibody was incubated with HRP-conjugated goat anti-rabbit IgG (H&L) secondary antibody (HY-P8001) (1:5000) diluted in 5% nonfat milk in TBST for 1 h at room temperature. Protein bands were visualized using an Ultra High Sensitivity ECL detection kit (HY-K1005).
  • Experimental Validation Results for Aurora B Antibody (YA6131)
    Western blot analysis of extracts from Hela (lane2(20μg), MCF-7 (lane3(20μg), A431 (lane4(20μg) and Jurkat (lane5(20μg) using Aurora B Antibody (HY-P86439). Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/4000) and Loading control antibody (Beta Actin, HY-P80993, 1/10,000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Rabbit IgG-HRP Secondary Antibody (HY-P8001 ,1/10,000) was used for 1 hour at room temperature.

Background

  • Function

    Aurora B (AURKB) is a mitotic serine/threonine kinase and the enzymatic core of the chromosomal passenger complex (CPC), which includes INCENP, Survivin, and Borealin[1]. Mechanistically, the CPC guides Aurora B through mitosis to control chromosome alignment, histone modification, kinetochore-microtubule error correction, spindle checkpoint signaling, and cytokinesis[1][2]. Therefore, Aurora B activity supports faithful chromosome segregation by releasing incorrect kinetochore-microtubule attachments, while reduced activity increases chromosome missegregation and aneuploid-cell generation[2]. In disease models, Aurora B deregulation or overexpression appears in several tumors, and studies in hepatocellular carcinoma, oral squamous cell carcinoma, prostate carcinoma, and glioblastoma connect Aurora B activity with recurrence, prognosis, tumor growth, or mitotic disruption[3][4][5][6]. Compared with related isoforms, Aurora A localizes to spindle poles and regulates mitotic entry, centrosome maturation, and spindle assembly, whereas Aurora B localizes with the CPC from inner centromeres to the spindle midzone and midbody[7]. Aurora C can act as a chromosomal passenger protein and complement Aurora B in mitotic cells, but Aurora B shows preferential INCENP binding and earlier M-phase expression[8]. For experimental applications, Aurora B or pan-Aurora inhibitors such as VX-680, AMG900, and danusertib help dissect metaphase-anaphase transition, cytokinetic initiation, mitotic progression, and cancer-cell proliferation[6][9][10].

  • Subcellular Localization

    Nucleus; Chromosome; Chromosome, centromere; Chromosome, centromere, kinetochore; Cytoplasm, cytoskeleton, spindle; Midbody

  • Expression


    Tissue_specificity:It is highly expressed in the thymus. It is also expressed in the spleen, lungs, testes, colon, placenta, and fetal liver. It is expressed in the S phase and G2/M phase, and its expression is upregulated in M phase cancer cells; it is not expressed in normal liver, but is highly expressed in metastatic liver.

    Induction:Expression is cell cycle-regulated, with a low in G1/S, an increase during G2 and M. Expression decreases again after M phase

  • Isoforms & Post-Translational Modification

    Q96GD4 has 5 isomers: Q96GD4-1: 39311 Da (predicted); Q96GD4-2: 35302 Da (predicted); Q96GD4-3: 16211 Da (predicted); Q96GD4-4: 34760 Da (predicted); Q96GD4-5: 39467 Da (predicted).
    The phosphorylation of Thr-232 requires the binding to INCENP and occurs by means of an autophosphorylation mechanism (PubMed:14722118). Thr-232 phosphorylation is indispensable for the AURKB kinase activity (PubMed:14722118, PubMed:26829474);Acetylated at Lys-215 by KAT5 at kinetochores, increasing AURKB activity and promoting accurate chromosome segregation in mitosis;Ubiquitinated by different BCR (BTB-CUL3-RBX1) E3 ubiquitin ligase complexes (PubMed:17543862, PubMed:19995937). Ubiquitinated by the BCR(KLHL9-KLHL13) E3 ubiquitin ligase complex, ubiquitination leads to removal from mitotic chromosomes and is required for cytokinesis (PubMed:17543862). During anaphase, the BCR(KLHL21) E3 ubiquitin ligase complex recruits the CPC complex from chromosomes to the spindle midzone and mediates the ubiquitination of AURKB (PubMed:17543862). Ubiquitination of AURKB by BCR(KLHL21) E3 ubiquitin ligase complex may not lead to its degradation by the proteasome (PubMed:19995937). Deubiquitinated by USP35; inhibiting CDH1-mediated degradation of AURKB (PubMed:29449677)

  • Subunit

    Component of the chromosomal passenger complex (CPC) composed of at least BIRC5/survivin, CDCA8/borealin, INCENP, AURKB or AURKC; predominantly independent AURKB- and AURKC-containing complexes exist (PubMed:11516652, PubMed:12925766, PubMed:14722118, PubMed:15249581, PubMed:18591255, PubMed:20562864, PubMed:27332895).

  • SwissProt ID

    Q96GD4

  • Gene ID
    9212 [NCBI]
  • Synonyms

    AURKB; AIK2; AIM1; AIRK2; ARK2; STK1; STK12; STK5; Aurora kinase B; Aurora 1; Aurora- and IPL1-like midbody-associated protein 1; AIM-1; Aurora/IPL1-related kinase 2; ARK-2; Aurora-related kinase 2; STK-1; Serine/threonine-protein kinase 12

References

[1]. Vader G, et al. The chromosomal passenger complex: guiding Aurora-B through mitosis. J Cell Biol. 2006 Jun 19;173(6):833-7. [Content Brief]

[2]. Abe Y, et al. System-level deficiencies in Aurora B control in cancers. Cell Cycle. 2016 Aug 17;15(16):2091-2092. [Content Brief]

[3]. Tanaka S, et al. Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy. Br J Surg. 2008 May;95(5):611-9. [Content Brief]

[4]. Pannone G, et al. Aurora B expression as a prognostic indicator and possible therapeutic target in oral squamous cell carcinoma. Int J Immunopathol Pharmacol. 2011 Jan-Mar;24(1):79-88. [Content Brief]

[5]. Cao M, et al. A Vector-Based Short Hairpin RNA Targeting Aurora B Suppresses Human Prostatic Carcinoma Growth. Technol Cancer Res Treat. 2017 Feb;16(1):112-119. [Content Brief]

[6]. Ryu J, et al. An Aurora kinase inhibitor, AMG900, inhibits glioblastoma cell proliferation by disrupting mitotic progression. Cancer Med. 2018 Nov;7(11):5589-5603. [Content Brief]

[7]. Carmena M, et al. Making the Auroras glow: regulation of Aurora A and B kinase function by interacting proteins. Curr Opin Cell Biol. 2009 Dec;21(6):796-805. [Content Brief]

[8]. Sasai K, et al. Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells. Cell Motil Cytoskeleton. 2004 Dec;59(4):249-63. [Content Brief]

[9]. Li Z, et al. The Aurora Kinase in Trypanosoma brucei plays distinctive roles in metaphase-anaphase transition and cytokinetic initiation. PLoS Pathog. 2009 Sep;5(9):e1000575. [Content Brief]

[10]. Meulenbeld HJ, et al. Danusertib, an aurora kinase inhibitor. Expert Opin Investig Drugs. 2012 Mar;21(3):383-93. [Content Brief]

View More

Aurora B Antibody (YA6131) Related Classifications

MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00

Measured by its ability to inhibit anti-CD3-induced proliferation of stimulated CTLL-2 mouse cytotoxic T cells. The ED50 this effect is 0.8023 μg/ml, corresponding to a specific activity is 1246.42 units/mg.

Assay Types
  • 1/16

    MedChemExpress Validation
     Western blot analysis was performed on protein extracts (25 μg) from HepG2 (lane 2), A549 (lane 3), Caco-2 (lane 4), MCF-7 (lane 5), HeLa (lane 6), and HT-1080 (lane 7) using Aurora B antibody. Proteins were transferred onto a 0.45 μm PVDF membrane using the Trans-Blot® Turbo™ system for 13 min. The membrane was then blocked with 5% nonfat milk in TBST (HY-K1025) for 1 h at room temperature. Thhe primary antibody (1:1000) and loading control antibody GAPDH Antibody (HRP) (HY-P80954A) (1:2500) were diluted in 5% nonfat milk in TBST and incubated with the membrane overnight at 4°C. After washing, the membrane of primary antibody was incubated with HRP-conjugated goat anti-rabbit IgG (H&L) secondary antibody (HY-P8001) (1:5000) diluted in 5% nonfat milk in TBST for 1 h at room temperature. Protein bands were visualized using an Ultra High Sensitivity ECL detection kit (HY-K1005).

  • 1/16

    MedChemExpress Validation
     Western blot analysis of extracts from Hela (lane2(20μg), MCF-7 (lane3(20μg), A431 (lane4(20μg) and Jurkat (lane5(20μg) using Aurora B Antibody (HY-P86439). Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/4000) and Loading control antibody (Beta Actin, HY-P80993, 1/10,000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Rabbit IgG-HRP Secondary Antibody (HY-P8001 ,1/10,000) was used for 1 hour at room temperature.

  • Aurora B Antibody (YA6131) Product Image
    1/16
  • Experimental Validation Results for Aurora B Antibody (YA6131)
  • Experimental Validation Results for Aurora B Antibody (YA6131)
  • Aurora B Antibody (YA6131) Product Image
  • Experimental Validation Results for Aurora B Antibody (YA6131)
    1/1
    MedChemExpress Validation
     Western blot analysis was performed on protein extracts (25 μg) from HepG2 (lane 2), A549 (lane 3), Caco-2 (lane 4), MCF-7 (lane 5), HeLa (lane 6), and HT-1080 (lane 7) using Aurora B antibody. Proteins were transferred onto a 0.45 μm PVDF membrane using the Trans-Blot® Turbo™ system for 13 min. The membrane was then blocked with 5% nonfat milk in TBST (HY-K1025) for 1 h at room temperature. Thhe primary antibody (1:1000) and loading control antibody GAPDH Antibody (HRP) (HY-P80954A) (1:2500) were diluted in 5% nonfat milk in TBST and incubated with the membrane overnight at 4°C. After washing, the membrane of primary antibody was incubated with HRP-conjugated goat anti-rabbit IgG (H&L) secondary antibody (HY-P8001) (1:5000) diluted in 5% nonfat milk in TBST for 1 h at room temperature. Protein bands were visualized using an Ultra High Sensitivity ECL detection kit (HY-K1005).
  • Experimental Validation Results for Aurora B Antibody (YA6131)
    1/1
    MedChemExpress Validation
     Western blot analysis of extracts from Hela (lane2(20μg), MCF-7 (lane3(20μg), A431 (lane4(20μg) and Jurkat (lane5(20μg) using Aurora B Antibody (HY-P86439). Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/4000) and Loading control antibody (Beta Actin, HY-P80993, 1/10,000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Rabbit IgG-HRP Secondary Antibody (HY-P8001 ,1/10,000) was used for 1 hour at room temperature.
  • Experimental Validation Results for Aurora B Antibody (YA6131)
  • Experimental Validation Results for Aurora B Antibody (YA6131)
  • Aurora B Antibody (YA6131) Product Image
    MedChemExpress Validation

    Western blot analysis was performed on protein extracts (25 μg) from HepG2 (lane 2), A549 (lane 3), Caco-2 (lane 4), MCF-7 (lane 5), HeLa (lane 6), and HT-1080 (lane 7) using Aurora B antibody. Proteins were transferred onto a 0.45 μm PVDF membrane using the Trans-Blot® Turbo™ system for 13 min. The membrane was then blocked with 5% nonfat milk in TBST (HY-K1025) for 1 h at room temperature. Thhe primary antibody (1:1000) and loading control antibody GAPDH Antibody (HRP) (HY-P80954A) (1:2500) were diluted in 5% nonfat milk in TBST and incubated with the membrane overnight at 4°C. After washing, the membrane of primary antibody was incubated with HRP-conjugated goat anti-rabbit IgG (H&L) secondary antibody (HY-P8001) (1:5000) diluted in 5% nonfat milk in TBST for 1 h at room temperature. Protein bands were visualized using an Ultra High Sensitivity ECL detection kit (HY-K1005).

  • Aurora B Antibody (YA6131) Product Image
    MedChemExpress Validation

    Western blot analysis of extracts from Hela (lane2(20μg), MCF-7 (lane3(20μg), A431 (lane4(20μg) and Jurkat (lane5(20μg) using Aurora B Antibody (HY-P86439). Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/4000) and Loading control antibody (Beta Actin, HY-P80993, 1/10,000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Rabbit IgG-HRP Secondary Antibody (HY-P8001 ,1/10,000) was used for 1 hour at room temperature.

  • Aurora B Antibody (YA6131) Product Image WB
  • Aurora B Antibody (YA6131) Product Image WB